InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025)

InMed Pharmaceuticals' Cost of Revenue history runs 5 years deep, the most recent figure standing at $635994.0 for Q4 2025.

• On a quarterly basis, Cost of Revenue fell 2.28% year-over-year to $635994.0 in Q4 2025; TTM through Dec 2025 was $3.2 million, a 1.43% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, down 7.46% from the prior year.
• Cost of Revenue slipped to $635994.0 in Q4 2025 per INM's latest filing, from $716962.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $1.3 million in Q2 2023 and bottomed at $127308.0 in Q1 2022.
• The 5-year median for Cost of Revenue is $728056.0 (2025), against an average of $668484.4.
• Across the five-year window, Cost of Revenue jumped 560.93% in 2023 and sank 37.99% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at $153537.0 in 2021, then jumped by 120.55% to $338620.0 in 2022, then jumped by 170.53% to $916058.0 in 2023, then declined by 28.96% to $650813.0 in 2024, then slipped by 2.28% to $635994.0 in 2025.
• Per Business Quant, the three latest INM Cost of Revenue figures stand at $635994.0 (Q4 2025), $716962.0 (Q3 2025), and $728056.0 (Q2 2025).